Merck's Keytruda is bound for new bladder cancer territory. But can it hold up against gene therapy?

Merck & Co.'s Keytruda could be the first PD-1/L1 inhibitor to enter the untapped non-muscle invasive bladder cancer realm thanks to an FDA priority review. However, a gene therapy has nabbed the same designation for the same setting, with phase 3 data expected this week.